Paperpal Prime Logo

Therapeutic Advances in Infectious Disease : Impact Factor & More

eISSN: 2049-937XpISSN: 2049-9361
JournalOpen Access

Key Metrics

CiteScore
1.5
SJR
Q4Infectious Diseases
SNIP
0.8
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Therapeutic Advances in Infectious Disease

Therapeutic Advances in Infectious Disease Journal Specifications

Overview
Publisher SAGE PUBLICATIONS LTD
Language English
Frequency Continuous publication
Article Processing ChargesUSD 1500
Publication Time9
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyContinuous publication
Publication Start Year2013
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 9
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC BY-NC
OA statementVisit website
View less

Planning to publish in Therapeutic Advances in Infectious Disease ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Therapeutic Advances in Infectious Disease

Multidrug-resistant <i>Candida auris</i> osteomyelitis treated with fosmanogepix and surgical source control: A report of a case with favorable outcome
  • 1 Oct 2026
  • Therapeutic Advances in Infectious Disease
Proceedings from Group B Strep in Pregnancy &amp; Babies Conference, Wednesday 20 May 2026, virtual meeting
  • 1 Oct 2026
  • Therapeutic Advances in Infectious Disease
Clinical characteristics, antimicrobial susceptibility patterns, and mortality predictors in patients with <i>Pseudomonas aeruginosa</i> urinary tract infection: A retrospective study
  • 1 Oct 2026
  • Therapeutic Advances in Infectious Disease
Histoplasmosis in Uganda: A fungal infection hidden behind tuberculosis, and a diagnostic pathway for a low-resource setting: A narrative review
  • 1 Oct 2026
  • Therapeutic Advances in Infectious Disease
Occult <i>Candida tropicalis</i> spondylodiscitis following severe polytrauma: A case report and literature review
  • 1 Oct 2026
  • Therapeutic Advances in Infectious Disease
Modeling the potential clinical and economic impact of clesrovimab for the prevention of RSV in infants in England and Wales
  • 1 Sep 2026
  • Therapeutic Advances in Infectious Disease
Multidrug-resistant <i>Candida auris</i> osteomyelitis treated with fosmanogepix and surgical source control: A report of a case with favorable outcome
  • 1 Oct 2026
  • Therapeutic Advances in Infectious Disease
Proceedings from Group B Strep in Pregnancy &amp; Babies Conference, Wednesday 20 May 2026, virtual meeting
  • 1 Oct 2026
  • Therapeutic Advances in Infectious Disease
Clinical characteristics, antimicrobial susceptibility patterns, and mortality predictors in patients with <i>Pseudomonas aeruginosa</i> urinary tract infection: A retrospective study
  • 1 Oct 2026
  • Therapeutic Advances in Infectious Disease
Histoplasmosis in Uganda: A fungal infection hidden behind tuberculosis, and a diagnostic pathway for a low-resource setting: A narrative review
  • 1 Oct 2026
  • Therapeutic Advances in Infectious Disease
Occult <i>Candida tropicalis</i> spondylodiscitis following severe polytrauma: A case report and literature review
  • 1 Oct 2026
  • Therapeutic Advances in Infectious Disease
Modeling the potential clinical and economic impact of clesrovimab for the prevention of RSV in infants in England and Wales
  • 1 Sep 2026
  • Therapeutic Advances in Infectious Disease

FAQs on Therapeutic Advances in Infectious Disease